

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Dagmar STIMMEDER :
Serial No. NEW : **Attn: APPLICATION BRANCH**
Filed November 7, 2003 : Attorney Docket No. 2003-1625
CARRIER WITH SOLID FIBRINOGEN AND :
SOLID THROMBIN :
(Rule 1.53(b) Continuation :
of Serial No. 10/054,853, :
Filed January 25, 2002) :

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicant requests consideration of ☒ the references listed on attached form PTO-1449 and/or ☐ the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 and each U.S. patent application listed below is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in prior parent application Serial No. 10/054,853.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page ,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Dagmar STIMMELDER

By



Nils E. Pedersen
Registration No. 33,145
Attorney for Applicant

NEP/krp
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
November 7, 2003

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: November 7, 2003

ATTY DOCKET NO.
2003-1625SERIAL NO.
NEWAPPLICANT
Dagmar STIMMEDERFILING DATE
November 7, 2003

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,453,939	6/1984	Zimmerman et al.			
	AB	4,606,337	8/1986	Zimmerman et al.			
	AC	5,942,278	8/1999	Hagedorn et al.			
	AD	6,177,126	1/2001	Hagedorn et al.			
	AE	5,942,278	8/1999	Hagedorn et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AF	0059265	9/1982	EP			partial
	AG	0748633A2	12/1996	EP			
	AH	00/15248	3/2000	WO			abstract
	AI	96/40033	12/1996	WO			
	AJ	97/37694	10/1997	WO			
	AK	99/56797	11/1999	WO			
	AL	99/59647	11/1999	WO			

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	A. L. Bloom et al., "Physiology of Blood Coagulation" 1990, pgs.14-29.
	AN	Torben Halkier, Chapter 5, Activation of prothrombin, pgs. 54-70.
	AO	Torben Halkier, Chapter 7, Formation and stabilisation of fibrin, pgs. 80-103.
	AP	Osada et al., "Clinical evaluation of a haemostatic and anti-adhesion preparation used to prevent post-surgical adhesion".

EXAMINER

DATE CONSIDERED